Jump to content

Arul Chinnaiyan

From Wikipedia, the free encyclopedia

Arul Chinnaiyan
Alma materUniversity of Michigan Medical School
Known forCancer Research
Scientific career
InstitutionsUniversity of Michigan Medical School, Howard Hughes Medical Institute

Arul M. Chinnaiyan is a Hicks Endowed Professor of Pathology and professor of pathology and urology at the University of Michigan Medical School.[1] He is also a Howard Hughes medical Investigator (HHMI) at the Howard Hughes Medical Institute.[2]

Arul Chinnaiyan received both PhD and MD degrees at the University of Michigan Medical School in 1999. He is a cancer researcher and the recipient of the 28th annual American Association for Cancer Research Award for Outstanding Achievement in Cancer Research at the annual meeting of the AACR in April 2008 in San Diego.[3] He was also the leader of a group of scientists who received the inaugural 2007 American Association for Cancer Research "Team Science" Award for their discovery of gene fusions in prostate cancer.[4]

Arul Chinnaiyan received a number of other awards and prizes, including the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research and of the Ramzi Cotran Young Investigator Award from the United States and Canadian Academy of Pathology. He is an elected member of the American Society for Clinical Investigation.[5]

He is a member of the editorial board for Oncogene.[6]

Research and discovery

[edit]

The focus of his research is molecular profiling of cancer to discover novel diagnostic markers and therapeutic targets. It is generally believed that blood cancers are caused by chromosome translocation such as Bcr-Abl in chronic myelogenous leukaemia (CML), whereas solid tumors are caused by mutations in growth or tumour suppressor genes. In research which challenges the current dogma, Arul has discovered chromosome translocation in solid prostate tumours. Arul has discovered that this translocation occurs between a male hormone related gene TMPRSS2 and transcription factors of the Erythroblast transformation specific (ETS) family.[7]

Publications

[edit]

Partial list:

References

[edit]
  1. ^ "University of Michigan Medical School Department of Pathology website". Archived from the original on 4 May 2007. Retrieved 21 April 2008.
  2. ^ HHMI: Arul M. Chinnaiyan, M.D., Ph.D
  3. ^ List of AACR Award for Outstanding Achievement in Cancer Research Winners Archived 5 May 2008 at the Wayback Machine
  4. ^ AACR Team Science Award Recipients Archived 10 March 2014 at the Wayback Machine, American Association for Cancer Research Award citation:"In recognition of their landmark discovery of recurrent gene fusions in a majority of prostate cancers, which has profound clinical and biological implications for understanding prostate cancers, and their embodiment of team science through interdisciplinary and inter-institutional collaboration."
  5. ^ 2 UMHS researchers selected as Howard Hughes Medical Institute investigators. Archived 21 April 2008 at the Wayback Machine University of Michigan Health System Press Release. 12 October 2007
  6. ^ "Editorial Board | Oncogene".
  7. ^ Tomlins, SA; Laxman, B; Dhanasekaran, SM; Helgeson, BE; Cao, X; Morris, DS; Menon, A; Jing, X; Cao, Q; Han, B; Yu, J; Wang, L; Montie, JE; Rubin, MA; Pienta, KJ; Roulston, D; Shah, RB; Varambally, S; Mehra, R; Chinnaiyan, AM (2007). "Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer". Nature. 448 (7153): 595–9. Bibcode:2007Natur.448..595T. doi:10.1038/nature06024. hdl:2027.42/62659. PMID 17671502. S2CID 4361134.